High-Throughput Screening – News and Features

A new study has measured the toxicity of several types of PFAS, better known as “forever chemicals,” when mixed together in the environment and in the human body.

A UCLA team created a biobank of sarcoma organoids from 126 patients, enabling rapid drug screening. The organoids retained tumor characteristics, allowing identification of effective FDA-approved treatments for 59% of samples.

High concentrations of organic micropollutants caused the death of fish, mussels and snails in the Oder river in 2022 by exacerbating the lethal effects of an algal toxin.

In this interview, Tola Olorunnisola, senior vice president and general manager at Avantor, delves into how AI and automation could put the Lab of the Future within our grasp, enabling scientific breakthroughs and revolutionizing the drug development process.

The ability to obtain pure proteins is essential for developing drugs, creating vaccines and understanding biological processes. In this article, we discuss what a typical protein purification protocol involves and the various techniques used.

At SLAS Europe 2024, Technology Networks had the pleasure of speaking with Jeroen Verheyen, CEO of Semarion, to discuss their award-winning work and how technological innovations advance research.

In this article, we explore how mass spectrometry imaging technology is evolving into a high-resolution spatial biology toolset to transform drug discovery and development.

Two winners earned the New Product Award at SLAS Europe 2024: SEED Biosciences’ Dispen3D and Cryologyx’s PlateReady™. Technology Networks spoke with CEO of CryoLogyx Tom Congdon to learn more about their award-winning new product.

UC Santa Cruz researchers have discovered a peptide in human RNA that regulates inflammation and may provide a new path for treating diseases such as arthritis and lupus.

Behind the scenes, as tumors progress and gain resistance to treatment, a protein called YB-1 quietly gives directions. Now, researchers have developed a first-of-its-kind drug that inhibits YB-1, effectively silencing those orders.